Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (HK:1858)
:1858
Top Page
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
(1858)
Select Model
Select Model
Rating:71Outperform
Price Target:
HK$14.50
▼(-5.78% Downside)
Action:UpgradedDate:04/08/26
The score is driven primarily by strong financial quality (high profitability and an exceptionally low-debt balance sheet), tempered by inconsistent revenue growth and cash-flow volatility. Technical indicators remain a headwind with the stock still below key longer-term moving averages, while valuation is moderately supportive (mid-range P/E and a modest dividend yield).
Positive Factors
High margins & profitability
The company’s persistently high gross and net margins create durable operating leverage and pricing power in its medical-device niche. Strong margins support reinvestment in R&D, sustain cash returns to stakeholders, and provide resilience against revenue volatility over the medium term.
Negative Factors
Inconsistent revenue growth
Consecutive annual revenue declines point to demand softness or loss of momentum in the company’s markets. Persistent top-line weakness undermines long-term margin expansion prospects and stresses the business model’s ability to scale profitably, constraining sustainable earnings growth.
Read all positive and negative factors
Positive Factors
Negative Factors
High margins & profitability
The company’s persistently high gross and net margins create durable operating leverage and pricing power in its medical-device niche. Strong margins support reinvestment in R&D, sustain cash returns to stakeholders, and provide resilience against revenue volatility over the medium term.
Read all positive factors
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$7.93B
Dividend Yield1.88%
Average Volume (3M)1.20M
Price to Earnings (P/E)19.3
Beta (1Y)1.16
Revenue Growth14.56%
EPS Growth61.60%
CountryHK
Employees1,237
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.23
Shares Outstanding95,140,500
10 Day Avg. Volume978,626
30 Day Avg. Volume1,198,522
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.71
Price to Sales (P/S)5.06
P/FCF Ratio14.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.81
Revenue Forecast (FY)HK$1.43B
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Beijing Chunlizhengda Medical Instruments Co., Ltd., an orthopedic medical device company, engages in the research and development, production, and sale of surgical implants, instruments, and related products in the People's Republic of China. It ...
How the Company Makes Money
null...
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.01B | 805.86M | 1.21B | 1.20B | 1.11B |
| Gross Profit | 639.61M | 516.49M | 875.89M | 913.53M | 854.54M |
| EBITDA | 299.86M | 169.32M | 340.65M | 366.96M | 360.99M |
| Net Income | 265.08M | 124.99M | 277.82M | 307.72M | 322.36M |
Balance Sheet | |||||
| Total Assets | 3.66B | 3.47B | 3.65B | 3.41B | 3.00B |
| Cash, Cash Equivalents and Short-Term Investments | 2.22B | 1.89B | 2.10B | 1.72B | 1.74B |
| Total Debt | 3.78M | 866.44K | 1.75M | 1.31M | 1.23M |
| Total Liabilities | 591.90M | 644.39M | 770.33M | 690.07M | 530.58M |
| Stockholders Equity | 2.99B | 2.82B | 2.88B | 2.72B | 2.47B |
Cash Flow | |||||
| Free Cash Flow | 351.97M | -51.07M | 478.47M | 16.10M | -34.62M |
| Operating Cash Flow | 409.57M | -1.90M | 511.71M | 41.01M | 164.79M |
| Investing Cash Flow | -124.01M | 55.84M | -81.56M | -762.61M | -190.35M |
| Financing Cash Flow | -28.75M | -183.14M | -121.33M | -59.04M | 1.07B |
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Technical Analysis
Neutral
15.39
Price Trends
13.41
Negative
14.79
Negative
15.02
Negative
Market Momentum
-0.01
Negative
52.58
Neutral
64.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1858, the sentiment is Neutral. The current price of 15.39 is above the 20-day moving average (MA) of 12.74, above the 50-day MA of 13.41, and above the 200-day MA of 15.02, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 52.58 is Neutral, neither overbought nor oversold. The STOCH value of 64.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1858.
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$6.39B | 18.20 | 6.19% | 2.76% | 13.59% | 6.31% | |
74 Outperform | HK$7.85B | 17.31 | 11.91% | 1.26% | 25.18% | 55.79% | |
71 Outperform | HK$7.93B | 19.30 | 9.39% | 1.88% | 14.56% | 61.60% | |
58 Neutral | HK$7.87B | 27.86 | 4.88% | 0.48% | 35.01% | 483.73% | |
57 Neutral | HK$8.21B | 16.88 | 1.98% | ― | 3.42% | -70.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.20B | -18.13 | -11.27% | ― | 29.25% | 9.02% |
* Healthcare Sector Average
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
13.26
4.41
49.83%
HK:9996
Peijia Medical Ltd.
6.26
1.80
40.36%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
22.88
6.99
44.01%
HK:1302
LifeTech Scientific Corporation
1.90
0.52
37.68%
HK:1763
China Isotope & Radiation Corp.
19.98
9.21
85.52%
HK:1789
AK Medical Holdings Ltd.
7.00
1.19
20.48%
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Corporate Events
Beijing Chunlizhengda Expands Asset Base on 2025 Annual Results
Mar 30, 2026
Beijing Chunlizhengda Medical Instruments reported its audited consolidated results for the year ended 31 December 2025, prepared under PRC accounting standards and Hong Kong listing rules. The group’s total assets rose to about RMB3.66 bill...
Beijing Chunlizhengda Board Sets March Meeting on 2025 Results and Dividend
Mar 13, 2026
Beijing Chunlizhengda Medical Instruments Co., Ltd., a Hong Kong-listed Chinese medical instruments maker, operates through a group structure that includes multiple subsidiaries. Its board comprises executive, non-executive and independent non-exe...
Beijing Chunlizhengda Posts Surge in 2025 Preliminary Profit on Revenue Growth
Feb 27, 2026
Beijing Chunlizhengda Medical Instruments Co., Ltd. reported strong preliminary results for 2025, driven by synergies between its domestic and international operations in the orthopedic medical device market. The company emphasized improved operat...
Beijing Chunlizhengda Forecasts Profit to Nearly Double in 2025 on Procurement and Overseas Growth
Jan 29, 2026
Beijing Chunlizhengda Medical Instruments Co., Ltd. expects a sharp jump in profitability for 2025, forecasting net profit attributable to shareholders of RMB244.99 million to RMB287.99 million, up about 96% to 130% year on year, and net profit ex...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.